Customer Demand Communication and Project Design
Projects begin with a consultation to understand your objectives and requirements, enabling us to tailor a bespoke project plan.
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
At Creative Biolabs, we stand as a leader in advanced biological solutions, offering unparalleled expertise in neutralizing antibody-based anti-monkeypox drug discovery. Our robust platforms and seasoned scientific team are dedicated to empowering clients with precise and effective therapeutic strategies against this emerging viral threat. We are committed to accelerating your research from concept to clinical translation.
Monkeypox virus (MPXV) is a double-stranded DNA virus belonging to the Orthopoxvirus genus within the Poxviridae family. It is a zoonotic pathogen, meaning it can transmit from animals to humans. MPXV infection typically manifests with a characteristic rash, fever, headache, muscle aches, and swollen lymph nodes. While generally less severe than smallpox, it can lead to significant morbidity and, in some cases, mortality, particularly in vulnerable populations. The virus exhibits complex replication cycles within host cells, making targeted antiviral interventions crucial for disease control.
Neutralizing antibodies, integral to the humoral arm of the adaptive immune system, are generated and secreted by B cells. These antibodies specifically bind to pathogens or infectious viruses, thereby preventing cellular infection by neutralizing their biological effects. This neutralization renders the pathogens or infectious viruses non-pathogenic or non-infectious.
For monkeypox, these antibodies primarily exert their antiviral effect by binding directly to viral surface proteins, such as glycoproteins on the enveloped virus, thereby preventing the virus from attaching to and entering human host cells. This binding can also inhibit conformational changes in viral proteins necessary for cellular entry or promote the degradation of virus-antibody complexes by macrophages, effectively disarming the pathogen and halting its infectious cycle.
Fig.1 Antiviral mechanism of neutralizing antibodies.1
Creative Biolabs provides a comprehensive suite of neutralizing antibody-based anti-monkeypox drug discovery solutions, meticulously designed to identify and develop highly potent and specific antibody therapeutics. Our integrated approach spans the entire discovery pipeline, ensuring a streamlined and efficient path from initial concept to lead candidate identification.
We offer the production of high-quality, biologically active MPXV recombinant proteins (e.g., A27, B5, L1) and Virus-Like Particles (VLPs) essential for robust antibody generation and screening.
Our advanced platforms include phage display, yeast display libraries, single B-cell sorting, and hybridoma technology, enabling the rapid isolation of diverse and high-affinity antibody candidates.
We develop and execute both safe pseudovirus neutralization assays and definitive live virus neutralization assays (conducted in BSL-2/3 facilities) to precisely quantify antibody efficacy.
Comprehensive characterization services include epitope mapping, affinity and avidity determination using SPR/BLI, developability assessment, and strategic Fc engineering to optimize antibody function.
While specific in vivo models for monkeypox NAb efficacy are complex and require specialized facilities, Creative Biolabs collaborates with partners to facilitate preclinical in vivo studies once lead candidates are identified. These studies aim to evaluate the protective efficacy and pharmacokinetic profiles of lead antibodies in relevant animal models, providing critical data for further development.
Projects begin with a consultation to understand your objectives and requirements, enabling us to tailor a bespoke project plan.
A detailed contract, outlining scope, deliverables, and timelines, is finalized upon mutual agreement, formalizing our partnership before project commencement.
Our expert scientists meticulously execute agreed procedures using cutting-edge platforms, providing regular progress updates.
Experienced bioinformaticians and scientists rigorously analyze data, providing comprehensive reports with clear interpretations and actionable insights.
Final results and data are delivered promptly. We offer ongoing consultation and technical support for post-delivery inquiries and future research.
Neutralizing antibodies hold diverse and significant applications in the fight against Monkeypox. Beyond their primary role in therapeutic drug development, they are invaluable as critical research tools for understanding viral pathogenesis and immune responses. NAbs can be employed in diagnostic assays to detect the presence of the virus or assess immune status. Furthermore, they serve as essential reagents for vaccine development, aiding in the identification of protective epitopes and evaluating vaccine efficacy. Their high specificity and potency also make them ideal candidates for passive immunization strategies, offering immediate, albeit temporary, protection to at-risk individuals.
Targeted Antigen Design
We prioritize the selection and production of immunogenic MPXV antigens, including conserved core proteins, to elicit broadly neutralizing antibody responses that can overcome viral genomic variations.
Integrated Discovery Workflow
Our seamless integration of various antibody discovery platforms, from phage display to hybridoma technology, ensures a highly efficient and comprehensive screening process.
Definitive Neutralization Assays
We offer both pseudovirus and live virus neutralization assays, providing robust and reliable data on the true antiviral potency of your antibody candidates.
Comprehensive Lead Optimization
Beyond simple binding, our services include detailed epitope mapping, developability assessment, and Fc engineering to ensure your lead antibodies are not only potent but also suitable for clinical development.
Expert Scientific Consultation
Our team of seasoned biologists and virologists provides continuous scientific guidance and support, ensuring your project benefits from decades of combined expertise in infectious disease and antibody therapeutics.
We specialize in producing a wide array of high-quality MPXV antigens. These include key envelope proteins such as A27, B5, and L1, which are crucial for viral entry and are excellent targets for neutralizing antibodies. We also offer the development of Virus-Like Particles (VLPs) that present these antigens in a more native, conformationally relevant form, optimizing the chances of eliciting potent neutralizing responses.
Our commitment to quality is paramount throughout the discovery process. We employ rigorous screening protocols across our advanced platforms, including phage display and single B-cell sorting, to identify antibodies with high affinity and specificity. Furthermore, all lead candidates undergo comprehensive characterization, including precise epitope mapping and detailed kinetic analysis, to confirm their binding characteristics and neutralizing potential.
Yes, we offer solutions for both monoclonal and polyclonal antibody development. For monoclonal antibodies, we leverage technologies like hybridoma and single B-cell sorting to isolate highly specific clones. For polyclonal antibodies, we can provide services to generate purified polyclonal antibodies with low batch-to-batch variation, which are beneficial for targeting multiple viral epitopes and addressing potential viral mutations.
The biosafety level required depends on the type of neutralization assay. For initial high-throughput screening, we primarily utilize safe pseudovirus neutralization assays, which can be conducted under BSL-2 conditions. However, for definitive validation and comprehensive assessment of lead candidates, we conduct live virus neutralization assays in appropriate BSL-3 facilities, ensuring both safety and the integrity of the experimental results.
Yes, we offer crucial downstream development support, including comprehensive developability assessment. This involves evaluating key antibody properties such as aggregation propensity, thermal stability, viscosity, and expression levels. Performing these assessments early in the discovery process is vital for predicting manufacturability and reducing the risk of costly failures in later stages of drug development.
We proactively address the challenge of viral mutations by focusing on identifying antibodies that target conserved epitopes on the MPXV. This strategy aims to develop antibodies that are less susceptible to viral escape mutations. Additionally, our ability to generate polyclonal antibodies, which bind to multiple epitopes, provides another layer of defense against viral genomic variations, offering broader protection.
Creative Biolabs offers a full range of neutralizing antibody-based anti-monkeypox drug discovery solutions to explore specific and robust neutralizing antibody therapeutics against monkeypox. Our sophisticated high-throughput screening, artificial intelligence, in vitro and in vivo platforms, and monkeypox detection services help to discover more specific monoclonal neutralizing antibodies that bind to a conserved epitope of the MPXV.
If you have the intention to customize the neutralizing antibody-based anti-monkeypox drug discovery solutions, please do not hesitate to contact us.
Reference
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.